Form 4: RAPT Therapeutics Chief Scientific Officer Amends Stock Options
SEC Form 4
RAPT Therapeutics' Chief Scientific Officer, Dirk G. Brockstedt, amended several employee stock options, resulting in the cancellation of old options and the grant of new ones with a lower exercise price.
Summary
- Dirk G. Brockstedt, the Chief Scientific Officer of RAPT Therapeutics, amended several of his employee stock options on November 13, 2024.
- These amendments involved the cancellation of existing options and the grant of new replacement options.
- The new options have a lower exercise price of $1.57 per share, compared to the previous prices ranging from $19.53 to $44.66.
- A total of 256,000 options were amended, with the same number of shares underlying both the old and new options.
- The options vest monthly over a four-year period from the original grant dates.
Sentiment
Score: 7
Explanation: The document reflects a positive change for the executive, but it is a routine transaction and not a major event for the company.
Positives
- The amendment of stock options provides the Chief Scientific Officer with a lower exercise price, potentially increasing the value of his options.
- The vesting schedule remains consistent, ensuring long-term alignment with the company's goals.
Industry Context
Stock option amendments are a common practice in the biotech industry to incentivize key personnel and align their interests with the company's performance.
Comparison to Industry Standards
- Stock option grants and amendments are standard practice for executive compensation in the biotechnology industry.
- The vesting schedules and terms of these options are generally consistent with industry norms.
- Companies like Amgen, Gilead, and Regeneron also use stock options as part of their executive compensation packages.
Stakeholder Impact
- The stock option amendments may have a minor positive impact on employee morale.
- The amendments do not have a direct impact on shareholders, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 01/30/2020 | Original grant date of one of the amended options. |
| 01/28/2021 | Original grant date of one of the amended options. |
| 01/01/2021 | Vesting start date for one of the amended options. |
| 01/28/2022 | Original grant date of one of the amended options. |
| 01/01/2022 | Vesting start date for one of the amended options. |
| 01/31/2023 | Original grant date of one of the amended options. |
| 01/01/2023 | Vesting start date for one of the amended options. |
| 01/01/2024 | Original grant date of one of the amended options. |
| 11/13/2024 | Date of the stock option amendments. |
| 11/15/2024 | Date of the SEC filing. |
| 01/29/2030 | Expiration date of some of the amended options. |
| 01/27/2031 | Expiration date of some of the amended options. |
| 01/27/2032 | Expiration date of some of the amended options. |
| 01/30/2033 | Expiration date of some of the amended options. |
| 01/30/2034 | Expiration date of some of the amended options. |
Keywords
stock options, employee stock options, RAPT Therapeutics, Dirk G. Brockstedt, option amendment, executive compensation, insider trading, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.